Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940282 | 1.00 | HDAC1 (0.53) | HDAC1HDAC6XIAPBIRC2CHRM4 | |
| SCHEMBL3565263 | 0.93 | HDAC6 (0.51) | HDAC1HDAC6XIAPBIRC2CHRM4 | |
| SCHEMBL846218 | 0.90 | HDAC1 (0.53) | HDAC1HDAC6CHRM4DRD2HTR7 | |
| SCHEMBL1270523 | 0.87 | CHRM4 (0.50) | HDAC1HDAC6XIAPBIRC2CHRM4 | |
| SCHEMBL29939759 | 0.87 | CHRM4 (0.50) | HDAC1HDAC6XIAPBIRC2CHRM4 | |
| SCHEMBL23063853 | 0.83 | HDAC1 (0.52) | HDAC1HDAC6UCHL1USP30KDM4E | |
| SCHEMBL1271119 | 0.83 | CHRM4 (0.48) | HDAC1HDAC6XIAPBIRC2CHRM4 | |
| SCHEMBL28834900 | 0.82 | NOTUM (0.60) | HDAC1HDAC6XIAPBIRC2KDM4E | |
| SCHEMBL14230676 | 0.82 | DRD2 (0.55) | BIRC2CHRM4DRD2HTR7ESR2 | |
| SCHEMBL28320901 | 0.81 | XIAP (0.56) | XIAPBIRC2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313292-B1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARM SPA (IT) | 2026-02-18 | — | — | EP | disclosed |
| EP-4313972-B1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-01-29 | — | — | EP | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4313972-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313292-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120434-A | Indoline derivatives as DDR1 and DDR2 inhibitors | 奇斯药制品公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117062812-A | Indoline derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2022200576-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022200577-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-29 | — | — | WO | disclosed |
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| CN-101263116-B | Novel heterobicyclic derivatives useful as liver carnitine palmitoyl transferase inhibitors | HOFFMAN-LA ROCHE LTD. (CH) | 2011-12-07 | — | — | CN | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101263116-A | Novel heterobicyclic derivatives useful as liver carnitine palmitoyl transferase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | HDAC1 580/4885HDAC6 1522/4885XIAP 2285/4885 |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | DDR1, DDR2, DDRGK1 | HDAC1 1463/4885HDAC6 1532/4885XIAP 1804/4885 |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | HDAC1 1625/4885HDAC6 1289/4885XIAP 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.